Symbols / SPRC $4.09 -27.09%
SPRC Chart
About
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.31M |
| Enterprise Value | — | Income | -6.48M | Sales | 1.31M |
| Book/sh | 142.32 | Cash/sh | — | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | 0.00 | Forward P/E | — | PEG | — |
| P/S | 1.77 | P/B | 0.03 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 3156.52 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | -12.81% | ROIC | — | Gross Margin | 38.74% |
| Oper. Margin | -5.70% | Profit Margin | 0.00% | Shs Outstand | 565.50K |
| Shs Float | 45.91K | Short Float | 2.72% | Short Ratio | 0.06 |
| Short Interest | — | 52W High | 94.50 | 52W Low | 3.76 |
| Beta | 1.28 | Avg Volume | 117.99K | Volume | 978.57K |
| Target Price | — | Recom | None | Prev Close | $5.61 |
| Price | $4.09 | Change | -27.09% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$4.02
Latest analyst target
3. DCF / Fair value
$47347.80
Fallback: EPS × 15 (assumed fair P/E). No FCF data; use with …
Ratings
Current target
$4.02
Low
—
High
—
Mean
—
- Quantum trials deal: NeuroThera swaps $9.46M stock for majority CliniQ stake - Stock Titan ue, 10 Mar 2026 13
- SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Sat, 07 Mar 2026 00
- Morning Market Movers: INKT, GSIW, ARQ, SPRC See Big Swings - RTTNews ue, 10 Mar 2026 12
- SciSparc Falls 12% After Announcing 1-for-9 Reverse Share Split - Nasdaq Mon, 02 Mar 2026 16
- SciSparc to cut outstanding shares to about 565K on Mar. 4 - Stock Titan Mon, 02 Mar 2026 13
- SciSparc stock tumbles after announcing MUSE system acquisition plans - Investing.com Mon, 01 Dec 2025 08
- Why Is SciSparc Stock (SPRC) Up 130% Today? - TipRanks Wed, 17 Sep 2025 07
- Why LFMD stock is recommended by analysts - July 2025 Earnings & Low Volatility Stock Recommendations - Naître et grandir Sat, 07 Mar 2026 06
- SciSparc (Nasdaq: SPRC) NeuroThera signs term sheet for 55% quantum data stake - Stock Titan ue, 02 Dec 2025 08
- SciSparc stock soars after acquiring GERD treatment technology - Investing.com Wed, 26 Nov 2025 08
- New GERD procedure tech puts SciSparc into a $2.5B device market - Stock Titan ue, 13 Jan 2026 08
- Nasdaq warns SciSparc its equity is too low to meet listing rules - Stock Titan Mon, 12 Jan 2026 08
- SciSparc targets $2.5B GERD device market with new MUSE patents - Stock Titan Mon, 26 Jan 2026 08
- SciSparc (Nasdaq: SPRC) closes MitoCareX sale; sellers to hold 40% of N2OFF (Nasdaq: NITO) - Stock Titan hu, 23 Oct 2025 07
- US$11.6M Pharma Assets: SciSparc to Transfer Portfolio; Expected to Hold 75–84% of Miza - Stock Titan Wed, 15 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -385.25 | 30.13K | 1.62M | 0.00 |
| TaxRateForCalcs | 0.00 | 0.23 | 0.23 | 0.00 |
| NormalizedEBITDA | -6.77M | -5.45M | -9.41M | -5.74M |
| TotalUnusualItems | -206.00K | 131.00K | 7.06M | -3.00K |
| TotalUnusualItemsExcludingGoodwill | -206.00K | 131.00K | 7.06M | -3.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -6.28M | -5.12M | -2.59M | -5.79M |
| ReconciledDepreciation | 482.00K | 538.00K | 187.00K | 33.00K |
| ReconciledCostOfRevenue | 800.00K | 683.00K | 322.00K | 0.00 |
| EBITDA | -6.97M | -5.31M | -2.35M | -5.74M |
| EBIT | -7.46M | -5.85M | -2.54M | -5.78M |
| NetInterestIncome | 391.00K | -9.00K | -1.24M | -18.00K |
| InterestExpense | 30.00K | 9.00K | 36.00K | 12.00K |
| InterestIncome | 421.00K | 0.00 | 0.00 | 0.00 |
| NormalizedIncome | -6.08M | -5.22M | -8.03M | -5.79M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -6.28M | -5.12M | -2.59M | -5.79M |
| TotalExpenses | 8.55M | 8.65M | 9.63M | 5.77M |
| TotalOperatingIncomeAsReported | -7.32M | -6.82M | -8.29M | -5.77M |
| DilutedAverageShares | 277.38K | 19.41K | 8.38K | 3.76K |
| BasicAverageShares | 277.38K | 19.41K | 8.38K | 3.76K |
| DilutedEPS | -22.65 | -263.84 | -309.38 | -1.55K |
| BasicEPS | -22.65 | -263.84 | -309.38 | -1.55K |
| DilutedNIAvailtoComStockholders | -6.28M | -5.12M | -2.59M | -5.79M |
| AverageDilutionEarnings | 0.00 | 0.00 | 0.00 | 0.00 |
| NetIncomeCommonStockholders | -6.28M | -5.12M | -2.59M | -5.79M |
| NetIncome | -6.28M | -5.12M | -2.59M | -5.79M |
| MinorityInterests | 1.19M | 761.00K | 0.00 | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | -7.47M | -5.88M | -2.59M | -5.79M |
| NetIncomeDiscontinuousOperations | 0.00 | |||
| NetIncomeContinuousOperations | -7.47M | -5.88M | -2.59M | -5.79M |
| TaxProvision | -14.00K | 22.00K | 14.00K | 0.00 |
| PretaxIncome | -7.49M | -5.86M | -2.58M | -5.79M |
| OtherIncomeExpense | -635.00K | -79.00K | 6.95M | -3.00K |
| SpecialIncomeCharges | -74.00K | -1.04M | 0.00 | 0.00 |
| GainOnSaleOfPPE | 1.27M | 0.00 | 0.00 | |
| WriteOff | 0.00 | 0.00 | ||
| ImpairmentOfCapitalAssets | 1.34M | 1.04M | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 907.00K | 0.00 | ||
| EarningsFromEquityInterest | -429.00K | -210.00K | -109.00K | 0.00 |
| GainOnSaleOfSecurity | -132.00K | 1.17M | 7.06M | -3.00K |
| NetNonOperatingInterestIncomeExpense | 391.00K | -9.00K | -1.24M | -18.00K |
| TotalOtherFinanceCost | -2.21M | 1.20M | 6.00K | |
| InterestExpenseNonOperating | 30.00K | 9.00K | 36.00K | 12.00K |
| InterestIncomeNonOperating | 421.00K | 0.00 | 0.00 | 0.00 |
| OperatingIncome | -7.24M | -5.77M | -8.29M | -5.77M |
| OperatingExpense | 7.75M | 7.97M | 9.31M | 5.77M |
| OtherOperatingExpenses | 128.00K | 110.00K | 80.00K | 135.00K |
| ResearchAndDevelopment | 1.81M | 1.73M | 2.96M | 2.00M |
| SellingGeneralAndAdministration | 5.80M | 6.13M | 6.27M | 3.64M |
| SellingAndMarketingExpense | 1.51M | 2.48M | 1.08M | 0.00 |
| GeneralAndAdministrativeExpense | 4.29M | 3.65M | 5.19M | 3.64M |
| OtherGandA | 3.36M | 3.17M | 4.12M | 3.37M |
| SalariesAndWages | 926.00K | 483.00K | 1.07M | 272.00K |
| GrossProfit | 506.00K | 2.20M | 1.02M | 0.00 |
| CostOfRevenue | 800.00K | 683.00K | 322.00K | 0.00 |
| TotalRevenue | 1.31M | 2.88M | 1.35M | 0.00 |
| OperatingRevenue | 1.31M | 2.88M | 1.35M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 515.63K | 33.65K | 12.45K | 5.66K |
| ShareIssued | 515.63K | 33.65K | 12.45K | 5.66K |
| TotalDebt | 46.00K | 76.00K | 27.00K | 63.00K |
| TangibleBookValue | 6.67M | 4.42M | 1.73M | 8.14M |
| InvestedCapital | 8.15M | 7.61M | 6.45M | 8.14M |
| WorkingCapital | 6.10M | 4.87M | 354.00K | 8.07M |
| NetTangibleAssets | 6.67M | 4.42M | 1.73M | 8.14M |
| CapitalLeaseObligations | 46.00K | 76.00K | 27.00K | 63.00K |
| CommonStockEquity | 8.15M | 7.61M | 6.45M | 8.14M |
| TotalCapitalization | 8.15M | 7.61M | 6.45M | 8.14M |
| TotalEquityGrossMinorityInterest | 8.94M | 9.59M | 6.45M | 8.14M |
| MinorityInterest | 785.00K | 1.97M | 0.00 | |
| StockholdersEquity | 8.15M | 7.61M | 6.45M | 8.14M |
| OtherEquityInterest | 11.75M | 11.28M | 10.93M | 10.08M |
| GainsLossesNotAffectingRetainedEarnings | 497.00K | 497.00K | 497.00K | 497.00K |
| ForeignCurrencyTranslationAdjustments | 497.00K | 497.00K | 497.00K | 497.00K |
| RetainedEarnings | -74.97M | -68.69M | -63.57M | -60.98M |
| CapitalStock | 70.89M | 64.53M | 58.59M | 58.54M |
| CommonStock | 70.89M | 64.53M | 58.59M | 58.54M |
| TotalLiabilitiesNetMinorityInterest | 1.41M | 1.59M | 4.16M | 1.77M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 9.00K | 24.00K | 0.00 | 18.00K |
| LongTermDebtAndCapitalLeaseObligation | 9.00K | 24.00K | 0.00 | 18.00K |
| LongTermCapitalLeaseObligation | 9.00K | 24.00K | 0.00 | 18.00K |
| CurrentLiabilities | 1.40M | 1.57M | 4.16M | 1.76M |
| OtherCurrentLiabilities | 341.00K | 532.00K | 2.74M | 359.00K |
| CurrentDebtAndCapitalLeaseObligation | 37.00K | 52.00K | 27.00K | 45.00K |
| CurrentCapitalLeaseObligation | 37.00K | 52.00K | 27.00K | 45.00K |
| CurrentDebt | 441.00K | |||
| OtherCurrentBorrowings | 441.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 130.00K | 104.00K | 77.00K | 38.00K |
| PayablesAndAccruedExpenses | 891.00K | 883.00K | 1.31M | 1.31M |
| CurrentAccruedExpenses | 75.00K | 48.00K | 1.00M | 45.00K |
| Payables | 816.00K | 835.00K | 312.00K | 1.27M |
| OtherPayable | 33.00K | 14.00K | 71.00K | |
| AccountsPayable | 816.00K | 802.00K | 298.00K | 1.20M |
| TotalAssets | 10.35M | 11.18M | 10.61M | 9.92M |
| TotalNonCurrentAssets | 2.84M | 4.74M | 6.09M | 92.00K |
| InvestmentsAndAdvances | 1.31M | 1.44M | 1.32M | 0.00 |
| InvestmentinFinancialAssets | 354.00K | 659.00K | 730.00K | 0.00 |
| LongTermEquityInvestment | 952.00K | 781.00K | 591.00K | 0.00 |
| InvestmentsinAssociatesatCost | 952.00K | 781.00K | 591.00K | 0.00 |
| GoodwillAndOtherIntangibleAssets | 1.48M | 3.19M | 4.72M | 0.00 |
| NetPPE | 59.00K | 108.00K | 57.00K | 92.00K |
| AccumulatedDepreciation | -40.00K | -117.00K | -65.00K | -22.00K |
| GrossPPE | 99.00K | 225.00K | 122.00K | 114.00K |
| Leases | 181.00K | 78.00K | 78.00K | |
| MachineryFurnitureEquipment | 24.00K | 44.00K | 44.00K | 36.00K |
| BuildingsAndImprovements | 75.00K | 181.00K | 78.00K | 78.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 7.50M | 6.45M | 4.51M | 9.82M |
| RestrictedCash | 20.00K | 65.00K | 60.00K | 45.00K |
| PrepaidAssets | 350.00K | 275.00K | 40.00K | 348.00K |
| Inventory | 113.00K | 742.00K | 668.00K | 0.00 |
| FinishedGoods | 113.00K | 742.00K | 668.00K | 0.00 |
| Receivables | 4.96M | 287.00K | 168.00K | 2.56M |
| OtherReceivables | 714.00K | 265.00K | 91.00K | 2.56M |
| DuefromRelatedPartiesCurrent | 15.00K | 0.00 | ||
| LoansReceivable | 4.22M | 0.00 | ||
| AccountsReceivable | 10.00K | 22.00K | 77.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 2.06M | 5.08M | 3.57M | 6.88M |
| OtherShortTermInvestments | 517.00K | 3.00M | 0.00 | |
| CashAndCashEquivalents | 1.54M | 2.08M | 3.57M | 6.88M |
| CashFinancial | 1.54M | 2.08M | 3.57M | 6.88M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.10M | -5.89M | -12.79M | -5.10M |
| RepaymentOfDebt | -54.00K | -47.00K | -70.00K | -207.00K |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 6.25M | 5.55M | 9.01M | 7.70M |
| CapitalExpenditure | -4.87M | -35.00K | ||
| EndCashPosition | 1.54M | 2.08M | 3.57M | 6.88M |
| BeginningCashPosition | 2.08M | 3.57M | 6.88M | 1.95M |
| EffectOfExchangeRateChanges | 0.00 | |||
| ChangesInCash | -536.00K | -1.50M | -3.30M | 4.93M |
| FinancingCashFlow | 6.19M | 8.48M | 11.70M | 10.06M |
| CashFlowFromContinuingFinancingActivities | 6.19M | 8.48M | 11.70M | 10.06M |
| NetOtherFinancingCharges | 2.98M | 3.00K | ||
| InterestPaidCFF | -8.00K | -7.00K | -8.00K | 0.00 |
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 2.77M | 2.57M |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 6.25M | 5.55M | 9.01M | 7.70M |
| CommonStockIssuance | 6.25M | 5.55M | 9.01M | 7.70M |
| NetIssuancePaymentsOfDebt | -54.00K | -47.00K | -70.00K | -207.00K |
| NetShortTermDebtIssuance | 0.00 | 0.00 | -188.00K | |
| ShortTermDebtPayments | 0.00 | 0.00 | -188.00K | |
| ShortTermDebtIssuance | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | -54.00K | -47.00K | -70.00K | -19.00K |
| LongTermDebtPayments | -54.00K | -47.00K | -70.00K | -19.00K |
| InvestingCashFlow | -1.62M | -4.09M | -7.08M | -70.00K |
| CashFlowFromContinuingInvestingActivities | -1.62M | -4.09M | -7.08M | -70.00K |
| NetOtherInvestingChanges | -4.03M | -5.00K | -15.00K | -35.00K |
| NetInvestmentPurchaseAndSale | 3.00M | -3.69M | -1.50M | 0.00 |
| SaleOfInvestment | 3.00M | |||
| PurchaseOfInvestment | 0.00 | -3.69M | -1.50M | 0.00 |
| NetBusinessPurchaseAndSale | -600.00K | -400.00K | -700.00K | 0.00 |
| SaleOfBusiness | 2.98M | 0.00 | 0.00 | |
| PurchaseOfBusiness | -600.00K | -400.00K | -700.00K | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -4.86M | 0.00 |
| PurchaseOfIntangibles | 0.00 | 0.00 | -4.86M | 0.00 |
| NetPPEPurchaseAndSale | 8.00K | 0.00 | -8.00K | -35.00K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | 0.00 | -8.00K | -35.00K | |
| OperatingCashFlow | -5.10M | -5.89M | -7.92M | -5.06M |
| CashFlowFromContinuingOperatingActivities | -5.10M | -5.89M | -7.92M | -5.06M |
| ChangeInWorkingCapital | 136.00K | -833.00K | -703.00K | 643.00K |
| ChangeInOtherWorkingCapital | -15.00K | |||
| ChangeInPayablesAndAccruedExpense | 45.00K | -405.00K | 39.00K | 473.00K |
| ChangeInPayable | 45.00K | -405.00K | 39.00K | 473.00K |
| ChangeInAccountPayable | 25.00K | -397.00K | 0.00 | 353.00K |
| ChangeInInventory | 629.00K | -74.00K | -668.00K | 0.00 |
| ChangeInReceivables | -523.00K | -354.00K | -74.00K | 170.00K |
| ChangesInAccountReceivables | 12.00K | 55.00K | -77.00K | 0.00 |
| OtherNonCashItems | -897.00K | -2.21M | -6.58M | 9.00K |
| StockBasedCompensation | 569.00K | 196.00K | 897.00K | 43.00K |
| AssetImpairmentCharge | 1.34M | 1.04M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 482.00K | 538.00K | 187.00K | 33.00K |
| DepreciationAndAmortization | 482.00K | 538.00K | 187.00K | 33.00K |
| OperatingGainsLosses | 734.00K | 1.26M | 879.00K | |
| EarningsLossesFromEquityInvestments | 429.00K | 210.00K | 109.00K | 0.00 |
| GainLossOnInvestmentSecurities | 305.00K | 1.05M | 770.00K | |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -7.47M | -5.88M | -2.59M | -5.79M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for SPRC
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|